Close Menu

More articles about Disease Areas

The collaboration seeks to standardize SARS-CoV-2 assays by defining concentrations of antibodies to specific viral proteins to confer neutralization.

The company and its collaborators previously published a study linking saliva concentrations of multiple microRNAs with concussion duration and symptoms in children.

The Belgian home testing company said it will use the money to initiate clinical development for a urine-based self-test for chlamydia and gonorrhea.

Hologic intends to use the proceeds of the offering and available cash to refinance its existing 4.375 percent senior unsecured notes due in 2025.

Federal mandates requiring frequent SARS-CoV-2 testing for nursing home employees and significant purchases of rapid antigen tests from HHS have raised concerns about capacity.

Overall, GenMark's ePlex Respiratory Pathogen Panel 2 provides results for more than 20 viruses and bacteria, including SARS-CoV-2, flu A and B, RSV, and rhinovirus.

dna strand image

In its IPO prospectus, the company shared plans to broaden the use of its methylation technology from cancer screening to diagnostics and residual disease monitoring.

The company said that dried blood-spot sampling improves access to HIV diagnostic testing and care, particularly among HIV-infected people living in remote areas.

The company's mobile app provides automated COVID-19 screening and directs potential patients to testing locations for confirmatory testing.

The agency is providing the material freely and asking for feedback, so it can fix possible problems before more widely disseminating it to labs and companies.

The method uses standard lab equipment and the nanoswitches can be easily reconfigured and made in large batches at a cost of about $0.01 per reaction.

Comparing the BD and Quidel rapid antigen tests showed they performed similarly despite sensitivity differences in initial FDA filings.

The company received Emergency Use Authorization from the US Food and Drug Administration last month for a SARS-CoV-2 total antibody test.

The company is selling 4,166,666 shares of its common stock at a price of $60 per share in the offering, which is expected to close Sept. 15.

FIND has convened the Access to COVID-19 Tools Accelerator Diagnostic Pillar to supply 500 million tests to countries in the next year.

The Swiss firm will offer 17,647,059 of its ordinary shares at $4.25 per share. It previously said it would offer $60 million worth of its shares.

The guidelines caution that there are "significant limitations" in the interpretation of polygenic risk scores and they should not be used in patient management.

 

The contractors will provide limited coverage for ctDNA tests if the patient has a personal history of stage II to stage III colorectal cancer.

A new study aims to compare the detection performance of Helio Health's circulating tumor DNA assay with that of other screening modalities.

The investment bank said that the company's noninvasive genomic test for melanoma detection could capture a large market currently served by invasive biopsies.

Pages